Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.
Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.
Currently, the quality outcome measures for palliative and end-of-life care focus more on end-of-life than upstream palliative care.
Outcomes for patients with hematologic malignancies appear to be worse across the board when managed by these measures compared with patients with solid tumors, says LeBlanc.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL